http://www.msunites.com/genentech-to...us-april-20th/


http://www.nationalmssociety.org/Abo...erapy-Designat


https://en.wikipedia.org/wiki/Ocrelizumab


" Ocrelizumab is a slightly modified version of Biogen/Genentech's existing therapy Rituxan/Rituximab. As Rituxan was approaching FDA approval for treatment of multiple sclerosis, it was simultaneously approaching the end of its patent. To avoid the profit loss of a new treatment that could have been available sooner and eventually in a generic form, Rituxan trials were halted and Ocrelizumab trials quickly began. "